Ticagrelor Tablet, Film Coated
Product Images NDC 72603-940

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 72603-940). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rxllc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ticagrelor-figure-1.jpg (Ticagrelor Figure 1)

A cumulative percentage curve graph comparing the effects of Ticagrelor 90 mg and Clopidogrel over 360 days from the first study drug dose, showing cumulative event percentages on the y-axis and days on the x-axis. The graph includes patient numbers at risk at various time points and summary statistics for event counts and 12-month Kaplan-Meier percentages for each drug.*

FDA Label Image

Ticagrelor-figure-10.jpg (Ticagrelor Figure 10)

A Kaplan-Meier cumulative incidence curve comparing Ticagrelor 90 mg tablets and Clopidogrel over 360 days from randomization. The y-axis shows cumulative percentage of events, and the x-axis indicates days from randomization. The chart includes a legend with patient numbers, event percentages, and hazard ratio statistics for Ticagrelor versus Clopidogrel, illustrating relative event rates over one year.*

FDA Label Image

Ticagrelor-figure-11.jpg (Ticagrelor Figure 11)

A forest plot chart comparing the hazard ratios (HR) with 95% confidence intervals of Ticagrelor versus Clopidogrel for various patient characteristics and treatment subgroups. The chart includes data for overall treatment effect, geographic region, ASA median dose, treatment approach, early PCI, CABG, diabetes history, prior TIA/stroke, glycoprotein inhibitor use, age group, sex, and race. Ticagrelor HRs are shown on the left and Clopidogrel HRs on the right, with a vertical line at HR=1 for reference.*

FDA Label Image

Ticagrelor-figure-12.jpg (Ticagrelor Figure 12)

A forest plot displaying hazard ratios (HR) with 95% confidence intervals for Ticagrelor versus Clopidogrel across different aspirin (ASA) dose groups (>=300 mg, >100-<300 mg, <=100 mg) in US and non-US regions. The plot includes numeric data tables for each group showing sample sizes (N), events (E), and HR values with confidence intervals, indicating comparative effectiveness.*

FDA Label Image

Ticagrelor-figure-13.jpg (Ticagrelor Figure 13)

A Kaplan-Meier survival curve chart showing cumulative event percentages over days from randomization. The chart compares Ticagrelor 90 mg, Ticagrelor 60 mg, and placebo groups, with cumulative percent on the vertical axis and days up to approximately 1300 on the horizontal axis. A table below shows the number at risk over time for each group, and an inset box provides patient and event counts, 36-month Kaplan-Meier percentages, hazard ratios with 95% confidence intervals, and p-values for the comparisons.*

FDA Label Image

Ticagrelor-figure-14.jpg (Ticagrelor Figure 14)

A forest plot chart showing the hazard ratios (HR) with 95% confidence intervals (CI) comparing Ticagrelor versus placebo across various patient subgroups. The chart details overall treatment effect and subgroups based on age, sex, race, weight, BMI, geographic region, history of myocardial infarction, diabetes status, coronary artery disease, creatinine clearance, stent type, smoking status, and time since prior treatments. Each subgroup's HR is represented by a square and a horizontal line depicting the confidence interval.*

FDA Label Image

Ticagrelor-figure-15.jpg (Ticagrelor Figure 15)

A line graph comparing cumulative percentage (%) over months from randomization for Ticagrelor and placebo groups. The x-axis represents months from 0 to 54, and the y-axis shows cumulative percentage from 0 to 14%. Two lines display event trends: a solid line for Ticagrelor and a dashed line for placebo, with corresponding event counts noted. A risk table below the x-axis shows sample sizes at risk over time for both groups.*

FDA Label Image

Ticagrelor-figure-16.jpg (Ticagrelor Figure 16)

A forest plot chart comparing Ticagrelor and Placebo across various patient characteristics. The chart displays hazard ratios (HR) with 95% confidence intervals for subgroups including age, sex, race, body mass index, geographic region, aspirin dose, baseline health metrics, history of cardiovascular conditions, and smoking status. The horizontal axis quantifies effectiveness where values left of center favor Ticagrelor and right favor Placebo.*

FDA Label Image

Ticagrelor-figure-17.jpg (Ticagrelor Figure 17)

A Kaplan-Meier cumulative incidence curve showing events over time comparing Ticagrelor 90 mg twice daily and placebo. The x-axis represents days from randomization up to 34 days, and the y-axis shows cumulative percentage of events. The graph includes numbers at risk for each group at various time points, with Ticagrelor having lower cumulative event percentages than placebo.*

FDA Label Image

Ticagrelor-figure-18.jpg (Ticagrelor Figure 18)

A forest plot chart comparing Ticagrelor versus placebo effects across various patient characteristics including age, sex, race, weight, BMI, geographic region, diagnosis, time to randomization and loading dose, diabetes, hypertension, prior conditions, statin treatment, and smoking status. It displays Hazard Ratios (HR) and 95% Confidence Intervals (CI) with corresponding event counts and percentages for each group, visually indicating treatment benefit or placebo favorability.*

FDA Label Image

Ticagrelor-figure-2.jpg (Ticagrelor Figure 2)

A bar chart showing the percentage of patients who had an event following CABG surgery over a period of 8 or more days, comparing two groups labeled T and C. The x-axis represents days, and the y-axis represents the percentage of patients with events. Bars for each day compare groups T (solid black) and C (striped). Below the chart are patient event counts and denominators for both groups at each day interval.*

FDA Label Image

Ticagrelor-figure-3.jpg (Ticagrelor Figure 3)

A line graph displaying the cumulative percentage of events over months from randomization, comparing Ticagrelor (solid line) with Placebo (dashed line). The x-axis shows time in months up to 54, and the y-axis shows cumulative percentage from 0 to 7%. The graph includes a legend with events out of total participants for both groups and a table indicating the number at risk over time.*

FDA Label Image

Ticagrelor-figure-4.jpg (Ticagrelor Figure 4)

A Kaplan-Meier cumulative percentage curve showing events over 34 days from randomization comparing Ticagrelor 90 mg twice daily (solid line) with placebo (dashed line). The graph includes numbers at risk for each group at different time points and a small table indicating event counts and KM% values for both groups.*

FDA Label Image

Ticagrelor-figure-5.jpg (Ticagrelor Figure 5)

A line graph comparing the percentage of IPA induced by 20uM ADP over time in hours for Ticagrelor 180 mg, Clopidogrel 600 mg, and a placebo. The graph shows higher IPA percentages for Ticagrelor, moderate for Clopidogrel, and low for placebo throughout the 8-hour period.*

FDA Label Image

Ticagrelor-figure-6.jpg (Ticagrelor Figure 6)

A line graph comparing the IPA (%) induced by 20uM ADP over time (days) for Ticagrelor, Clopidogrel, and Placebo. Ticagrelor shows the highest initial IPA, peaking near 90%, then decreasing over 10 days. Clopidogrel starts around 60%, decreasing steadily, while Placebo remains low throughout. An inset graph shows IPA (%) induced by 20uM ADP over hours (0 to 48), with similar trends: Ticagrelor highest, Clopidogrel moderate, and Placebo low.*

FDA Label Image

Ticagrelor-figure-7.jpg (Ticagrelor Figure 7)

A chart titled 'Mean effect and 90% CI' comparing Ticagrelor and AR-C124910XX across various intrinsic factors including age, gender, ethnicity, renal impairment, end-stage renal disease on hemodialysis, and mild hepatic impairment. The chart uses markers to show change relative to reference values for Cmax (black squares) and AUC (black triangles), with a recommendation column indicating 'No dose adjustment' for all factors.*

FDA Label Image

112 (Ticagrelor Figure 8)

A forest plot chart displaying mean effect and 90% confidence intervals for ticagrelor's drug interactions with various agents such as ketoconazole, diltiazem, rifampin, aspirin, desmopressin, heparin, enoxaparin, cyclosporine, morphine, and fentanyl. The chart presents changes relative to reference for pharmacokinetic parameters Cmax and AUC, accompanied by clinical use recommendations.*

FDA Label Image

Ticagrelor-figure-9.jpg (Ticagrelor Figure 9)

A forest plot illustrating the mean effect and 90% confidence interval (CI) of Ticagrelor drug interactions with various interacting drugs at specified doses. The x-axis shows the change relative to the interacting drug alone. The plot includes CMAX and AUC values for each drug interaction, with recommendations such as dose adjustment guidance or references to specific sections for details.*

FDA Label Image

Str (Ticagrelor Str)

Chemical structure of Ticagrelor, illustrating its molecular composition and arrangement of atoms and bonds in the active ingredient.*

FDA Label Image

112 (Ticagrelor Tablets 60mg 60s)

Label for Ticagrelor Tablets 60 mg film-coated tablets by NorthStar Rx LLC. The label includes dosage information, storage instructions, a warning to keep out of reach of children, barcodes, and manufacturer details. The package contains 60 tablets.*

FDA Label Image

112 (Ticagrelor Tablets 90 mg 60s)

Ticagrelor 90 mg film-coated tablets label showing the proprietary name and strength prominently. The label states the NDC number 72603-941-01, indicates 60 tablets per package, and specifies dispensing instructions for pharmacists. It includes barcodes and storage conditions, manufacturer information for NorthStar Rx LLC in Memphis, TN, and mentions the medication guide availability. The label features a blue and white design with orange highlighting the strength.*

FDA Label Image

112 (Ticagrelor Tablets 90mg 100s)

Ticagrelor 90 mg film-coated tablets label from NorthStar Rx LLC. The label indicates this is a prescription drug with 100 tablets per package. It includes storage instructions, a warning to keep out of reach of children, and manufacturing details for NorthStar Rx LLC and Macleods Pharmaceuticals Ltd. The label also references a Medication Guide and provides website and contact information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.